Quintiles Transnational Holdings Inc (Q) : Pensionfund Sabic added new position in Quintiles Transnational Holdings Inc during the most recent quarter end. The investment management firm now holds 22,000 shares of Quintiles Transnational Holdings Inc which is valued at $1.5 Million according to a report filed by the company on Apr 4, 2016 with the SEC.Quintiles Transnational Holdings Inc makes up approximately 0.47% of Pensionfund Sabic’s portfolio.
Other Hedge Funds, Including , Pensionfund Dsm Netherlands added Q to its portfolio by purchasing 49,000 company shares during the most recent quarter which is valued at $3.4 Million. Quintiles Transnational Holdings Inc makes up approx 0.47% of Pensionfund Dsm Netherlands’s portfolio.
On the company’s financial health, Quintiles Transnational Holdings Inc reported $0.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Feb 11, 2016. Analyst had a consensus of $0.87. The company had revenue of $1129.00 million for the quarter, compared to analysts expectations of $1126.97 million. The company’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS.
Many Wall Street Analysts have commented on Quintiles Transnational Holdings Inc. Quintiles Transnational Holdings Inc was Downgraded by Sun Trust Rbsn Humphrey to ” Neutral” on Mar 28, 2016. Quintiles Transnational Holdings Inc was Upgraded by Avondale to ” Mkt Perform” on Feb 11, 2016.
Quintiles Transnational Holdings Inc closed down -0.48 points or -0.68% at $70.35 with 12,82,891 shares getting traded on Monday. Post opening the session at $71.23, the shares hit an intraday low of $70.05 and an intraday high of $71.44 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.